LakeShore Biopharma Co., Ltd (LSB)
NASDAQ: LSB · Real-Time Price · USD
0.7425
-0.0234 (-3.06%)
Aug 14, 2025, 11:37 AM - Market open

LakeShore Biopharma Cash Flow Statement

Millions CNY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Net Income
-99.98-433.46-145.48-236.67-208.44
Depreciation & Amortization
36.6542.1936.6931.1527.91
Loss (Gain) From Sale of Assets
9.780.01-0.270.02
Asset Writedown & Restructuring Costs
33.8280.24---
Stock-Based Compensation
13.569.793.517.7676.76
Provision & Write-off of Bad Debts
2.894.9910.755.086.41
Other Operating Activities
-2.3246.814.81143.7837.41
Change in Accounts Receivable
-59.6513.9-165.25-99.14-220.73
Change in Inventory
-24.17-86.26-18.15-89.46-68.73
Change in Accounts Payable
-18.22-12.6649.6314.43-4.42
Change in Unearned Revenue
-4.63-3.61-6.45-0.66-0.04
Change in Income Taxes
-----34.11
Change in Other Net Operating Assets
-8.7142.8447.4749.89141.35
Operating Cash Flow
-120.98-295.23-182.47-173.55-246.61
Capital Expenditures
-12.71-44.25-52.76-295.31-104.88
Sale of Property, Plant & Equipment
0.85-0.070.010.64
Sale (Purchase) of Intangibles
-5.15--4.29-3.62-
Investing Cash Flow
-17.01-44.25-56.98-298.92-104.24
Short-Term Debt Issued
----299.76
Long-Term Debt Issued
334.82337.85247.39414.1232.25
Total Debt Issued
334.82337.85247.39414.12332.01
Short-Term Debt Repaid
-----163.35
Long-Term Debt Repaid
-338.4-416.79-146.51-49.56-160.41
Total Debt Repaid
-338.4-416.79-146.51-49.56-323.75
Net Debt Issued (Repaid)
-3.58-78.93100.88364.568.26
Issuance of Common Stock
-284.2--1.59
Other Financing Activities
--216.57--
Financing Cash Flow
-3.58205.26317.45364.56739.26
Foreign Exchange Rate Adjustments
2.510.421.3-11.48-0
Net Cash Flow
-139.07-123.8299.3-119.39388.41
Free Cash Flow
-133.69-339.48-235.23-468.86-351.49
Free Cash Flow Margin
-21.74%-59.20%-34.23%-93.22%-136.76%
Free Cash Flow Per Share
-6.98-31.75-38.07-75.83-56.85
Cash Interest Paid
23.2230.1327.292.48.12
Cash Income Tax Paid
3.37---34.11
Levered Free Cash Flow
-210.46-216.49-187.61-465.23-
Unlevered Free Cash Flow
-200.63-188.77-168.33-463.53-
Change in Working Capital
-115.38-45.79-92.75-124.94-186.68
Updated Aug 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q